Abstract:Background: Poor trafficking, exhaustion and low persistence of adoptively transferred T and NK cell-based therapies in solid tumors remain major barriers in the field. Leveraging safety, tumor tropism and ease of genetic manipulation in bacteria present potentially a novel approach to overcome these barriers. Prior approaches to bacteria-based biologics delivery encounter issues of low concentration and fast clearance. In this study, we hypothesized that displaying immune-activating cytokines on outer membrane of Escherichia coli (E. coli) could modulate immunosuppressive tumor microenvironment (TME) enhancing migration, activation, and tumor control mediated by T and natural killer (NK) cells. Methods: To investigate our hypothesis, we expressed human and murine cytokines: IL-15, decoy resistant IL-18 (DR-18), and IL-21 on outer membrane of a non-pathogenic facultative bacteria E. coli K-12. We first evaluated their ability to activate human mesothelin (MSLN) NK cell CARs in vitro and performed gene expression analysis. For the in vivo experiments we used C57BL/6 mouse model with syngeneic tumor cell lines MC38 and B16F10. We also assessed the ability of human cytokine-displaying bacteria with human MSLN-CAR NK cells in NSG mice carrying human mesothelioma H226. Results: OmpA displaying murine DR-18 on bacterial surface was most effective in tumor control. After optimization, intra-tumoral injection of the bacteria resulted in 50% of cured mice bearing MC38 and 30% of cured mice bearing B16F10. Rechallenging these mice with respective cells showed no tumor growth, indicating induction of tumor-specific immune memory. Tumor tissue analysis showed upregulation of CD8 T and NK cells and depletion experiments demonstrated the contribution of these cells to tumor control. When systemically injected, the bacteria inhibited tumor growth with no side effects. Bio-distribution analysis demonstrated bacterial enrichment in TME. Through the utilization of in vitro killing assays by NK cells, YiaT232 scaffold with human DR-18 emerged as the optimal candidate. RNA-sequencing demonstrated that bacteria with DR-18 were capable of upregulating IL-12 and oxidative phosphorylation pathway in NK cells. Furthermore, administration of bacteria displaying DR-18 and systemic (IV) MSLN-CAR-NK cells led to better tumor control (vs soluble DR-18 or bacteria alone) in NSG mice carrying mesothelin-high H226. Conclusions: Here we develop a novel platform for immunotherapy involving surface display of cytokines in non-pathogenic E. coli. The bacteria were safe and demonstrated tumor tropism and CD8 T and NK cells were identified as the major effector cells mediating tumor control in immune-competent mice. Subsequently, we could display human DR-18 on these bacteria which resulted in superior tumor control in NSG mice when combined with MSLN-CAR-NK cells, paving the way for clinical translation in the near future. Citation Format: Shaobo Yang, Michal Sheffer, Isabel Kaplan, Zongqi Wang, Mubin Tarannum, Roman Shapiro, Yasmin Abdulhamid, Rebecca Porter, David Barbie, Robert Soiffer, Jessica Little, Jerome Ritz, Mengdi Yang, Valeria Márquez-Pellegrin, Jiahe Li, Rizwan Romee. Nonpathogenic E. coli engineered to surface display human cytokines for enhanced immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3608.

Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses

Abstract 3608: Nonpathogenic E. coli engineered to surface display human cytokines for enhanced immunotherapy

Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy

Spatiotemporal Delivery of Dual Nanobodies by Engineered Probiotics to Reverse Tumor Immunosuppression via Targeting Tumor-Derived Exosomes

Durable Antitumor Response Via an Oncolytic Virus Encoding Decoy-Resistant IL-18

Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity.

Oral Probiotics Microgel Plus Galunisertib Reduced TGF-β Blockade Resistance and Enhanced Anti-tumor Immune Responses in Colorectal Cancer

Abstract 584: Driving anti-tumor activity in solid tumors with controlled arming of allogeneic CAR-NK cells

Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin

Abstract 6639: Mechanisms of action of a killed, bacteria-based, multiple immune receptor agonist in development for pulsed anti-tumor immunotherapy

Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia

Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies

Dual-responsive natural killer cell nano-engagers for cancer immunotherapy via inhibiting IL-6/JAK2/STAT3 pathway

Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy

Endoplasmic Reticulum-Targeted Delivery of Celastrol and PD-L1 Sirna for Reinforcing Immunogenic Cell Death and Potentiating Cancer Immunotherapy

Continuous Release of Interleukin 12 from Microencapsulated Engineered Cells for Colon Cancer Therapy

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Nanobody‐Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy

Tumor Colonization and Therapy by Escherichia coli Nissle 1917 Strain in Syngeneic Tumor-Bearing Mice Is Strongly Affected by the Gut Microbiome